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INTRODUCTION
Renal transplantation has revolutionized the manage-
ment of end-stage renal disease (ESRD). Although
advances in transplantation technology and immunology
have resulted in dramatic improvement in outcome,
paediatric recipients have not shared in this improve-
ment.1 Technical,2 metabolic,3 immunological,4 and
psychological factors make transplants in children
challenging and unique. The effects of uraemia are more
pronounced in children. With problems of access for dialysis,
it is generally agreed that renal transplantation is the best
mode of renal replacement therapy for children.5
Paediatric renal transplantation is uncommon in our
country. It is a difficult and a challenging endeavour, both
from the anaesthetic as well as the surgical point of view.
The problems of long-term management of immuno-
compromised children who are still growing creates a
further dilemma. We present our experience with
paediatric renal transplants over a 15-year period.
METHODS
This was a retrospective study of 63 children, less than
15 years of age, who underwent living-related renal
transplantation in the Christian Medical College and
Hospital Vellore between 1984 and 1996. Profile of native
kidney disease leading to end-stage renal disease and
outcome of renal transplantation in terms of patient survival,
graft survival, weight gain and increase in height were
studied.
OBJECTIVE: To review the outcome of paediatric renal transplantation over a period of 15 years in
a developing country.
METHODS: This is a retrospective study of 63 children, less than 15 years of age, who underwent
living-related renal transplantation in Christian Medical College and Hospital Vellore between 1984
and 1996.
RESULTS: The records of 12 patients were not adequate for detailed analysis. Parents were the
donors for these children in 84.3% of cases. The most common known cause of end-stage renal disease
in these children was reflux nephropathy. Combinations of cyclosporine, azathioprine and prednisolone
were used as immunosuppressive drugs. Complications occurred in 16 patients. During the follow-up
period, eight patients died and two returned to receiving haemodialysis. Patient survival was 92% at
the end of 1 year and 90% at the end of 3 years. Graft survival was 88% and 86% at 1 and 3 years,
respectively.
CONCLUSION: Our study validates the concept of renal transplantation as optimal therapy with
adequate medical, social and functional rehabilitation for children with end-stage renal disease. Our
study also indicates that vesicoureteric reflux appears to be underdiagnosed and should be actively
pursued to prevent complications. (Asian J Surg 2002;25(3):198–202)
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RESULTS
There were 48 boys and 15 girls who received 64 renal
grafts. The records of 12 patients were not adequate for
detailed analysis. The mean age (± standard deviation,
SD) at transplantation was 12.86 years (± 2.52). One third
of the patients were younger than 12 years. Parents were
the donors for these children in 84.3% (Figure 1). The mean
age of donors (± SD) was 37.01 years (± 8.72). The mean
weight of the children (± SD) was 30.61 kg (± 5.35) at the
time of surgery and they gained, on average, 3.89 kg/year.
The causes of ESRD in these children are listed in Table 1.
Figure 2 the describes the technical details regarding
vascular anastomosis. In one patient, the Politano-
Leadbetter technique of ureteric reimplantation6 was
used, while in the rest, ureters were re-implanted using
the anterior extravesical tunnel technique.7 The
immunosuppressive protocol used for these transplants is
shown in Table 2. Two patients had an abnormal bladder
with poor compliance requiring drug modulation with
anticholinergics following transplantation.
 Complications occurred in 16 patients (Table 3). The
average follow-up period was 29 months (range, 12–137
months). During this period, eight patients died and
two returned to haemodialysis. Another two patients
required native kidney nephrectomy for control of
hypertension. Survival data for these patients are shown in
Table 4.
DISCUSSION
The incidence of ESRD is about three per million in the
West.8 Although the exact incidence in India is not
available, it may not be very different from the above
figure. The causes of renal failure in this study were not
significantly different from those reported in Western
literature.9–11 The patients in our study had a higher
incidence of reflux nephropathy compared to those in the
Figure 1. Donor distribution.
Table 1. Native kidney disease
Unknown 20
Medical 25
  Reflux 8
  Focal segmental glomerulosclerosis 7
  Hereditary nephritis 3
  Membrano-proliferative glomerulonephritis 2
  Systemic lupus erythematosus 1
  Others 4
Surgical 6
  Posterior urethral valves 4
  Bilateral stone 1
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Table 2. Immunosuppression protocol
Cyclosporine + azathioprine + prednisolone 11
Cyclosporine + prednisolone 21
Prednisolone + azathioprine 18
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West, probably because the diagnosis was initially missed
due to inadequate primary health care. Our patients
presented at a much later stage of their disease and the
cause of renal failure could not be assessed in 39.6%.
Urological problems, such as obstructive uropathy (16.9%)
account for a significant proportion of patients progressing
to ESRD, requiring renal replacement therapy.9 In our
study, urological problems did not appear to be the cause.
We can only presume that many patients with urological
problems died before they were seen by a renal physician.
The modalities of treatment available for children with
ESRD include renal transplantation, chronic ambulatory
peritoneal dialysis and chronic haemodialysis. Renal
transplantation is the best option. In our institution, only
relatives are accepted as live donors and mothers were the
commonest (63.36 %).
Modification of the surgical technique, e.g., using
more proximal vessels, was carried out in 25.7% of
patients, because of the disparity in the size of the vessels
and space available for the graft. It was possible to place
the grafts extraperitoneally (only one graft was placed
intraperitoneally). No technical difficulties were
encountered in our study. Apart from one graft artery with
stenosis, which was treated by angioplasty, no vascular
complications were encountered. The reported incidence
of vascular complications is around 15%.12 Subsequent
surgical procedures were required in two patients: one for
vesicocutaneous fistula repair and one for reflux in the
allograft ureter.
The immunosuppressive protocols used in paediatric
and adult renal transplantation are similar. However,
there are subtle differences in drug dosage because children
have a smaller intestinal surface area, increased rate of
metabolism and a high growth requirement. When
compared to adults, children require higher or more
frequent dosing with oral cyclosporine. Data from the
North American Pediatric Renal Transplant Cooperative
Study (NAPRTCS) showed a correlation between higher
cyclosporine dosing and improved allograft survival in
living- and cadaver-donor kidney transplants.13 With the
use of cyclosporine, corticosteroid dosages have
decreased.13 Attempts to wean children completely off
steroids have been largely unsuccessful due to subsequent
acute rejection rates, which can be as high as 60%.15,16
Daily corticosteroid therapy can adversely affect growth.
Consequently, some paediatric renal transplant recipients
fail to attain the accelerated growth rates needed to reach
normal adult height. Alternate-day corticosteroid therapy
can result in accelerated growth in some patients, especially
in young recipients with good allograft function.17 Most
prospective studies and a retrospective analysis of the
NAPRTCS database showed similar acute rejection rates
in children on alternate-day therapy compared with
patients given daily corticosteroids.18–20 Most centers
reserve alternate-day corticosteroid therapy for children,
1 or more years following transplantation, who have not
had acute rejection or noncompliance. Tacrolimus is a
newer agent that has been used with increasing success
for renal and multi-organ transplantation and has produced
excellent long-term graft survival. The major advantage
of this agent is the concomitant ability to taper and
eliminate corticosteroids in up to 60% of paediatric
kidney recipients.21
Our current immunosuppressive protocol includes
cyclosporine, azathioprine and prednisolone,
administered in doses of 12.5 mg/kg, 1 to 1.5 mg/kg and
0.4 mg/kg, respectively, which were reduced over a
period of time. Cyclosporine was stopped after 1 year or
more. None of our patients was on alternate-day
corticosteroid therapy.
We prefer to reconstruct the urinary tract using an
unstented extravesical ureteroneocystostomy. This
approach reduces the risk of postoperative haematuria,
urinary extravasation and bladder spasm because a




Acute tubular necrosis 2
Urinary tract infection 1
Surgical 4
Ureteric obstruction 1
Graft artery stenosis 1
Vesicocutaneous fistula 1
Reflux 1
Table 4. Survival data
At 1 Year At 3 years
Patient 92.16% 90.2%
Graft 88.24% 86.28%
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4.2% incidence of urinary leakage requiring re-operation
and a 2.4% incidence of distal ureteral obstruction in 166
consecutive renal transplantations in children.22 After
changing from the Politano-Leadbetter type ureteral re-
implant to an extravesical approach, they had no further
cases of urinary leakage during the ensuing 4 years.
Sheldon et al prefered extravesical ureteroneocystostomy
and reported only one case of urinary extravasation and
no cases of distal ureteral obstruction in 303 paediatric
renal transplants.23
Acute rejection episodes are difficult to diagnose in
children, in view of large renal reserve and low muscle
mass. Renal allograft biopsy and periodic follow-up with
measurement of serum creatinine levels help establish
this diagnosis. Most patients respond favourably to prompt
anti-rejection therapy. Graft survival at the end of 1 year
was 88% and at the end of 3 years was 86%. Actuarial
patient survival at the end of 1 year was 92% and at the
end of 3 years was 90%. Short-term graft survival in
paediatric patients is typically equivalent to that reported
for adults, with 1 year graft survival of 88% following
living related donor transplantation and 71% following
cadaver donor renal transplantation.24 Our study is similar
to those reported by others.
Various urological complications, including vascular
problems, have been described in these patients.25–27
Lymphoproliferative disorders are described as the most
common new malignancy in paediatric kidney transplant
recipients.11
Aseptic necrosis of the femoral head and malignancy
were not seen in our patients. Emotional and social pro-
blems have been described in paediatric renal transplant
patients due to undesirable side effects of steroids. These
were not encountered in any of our patients.
CONCLUSION
 Our study validates the concept of renal trans-
plantation, in combination with adequate medical, social
and functional rehabilitation, as optimal therapy for
children with ESRD.
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